Mechanism of Action of Transcranial Magnetic Stimulation
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Enrollment
- 54
- Locations
- 1
- Primary Endpoint
- Changes in Functional Connectivity of Key Nodes in Depression
Study Overview
Brief Summary
This is an observational neuroimaging study assessing the effects of TMS on the brains of patients with unipolar depression.
Detailed Description
This project aims to use functional connectivity magnetic resonance imaging (fcMRI) to study patients with unipolar depression receiving TMS. Patients will be scanned before and after a full course of TMS and clinical measures for depression severity and memory will be obtained at the same times.The project has the following aims and hypothesis: (1) to determine the therapeutic antidepressant mechanism of action of TMS at the circuit level (2) to study the use of fcMRI as a state biomarker for depression (3) to study the use of fcMRI as a predictor of response for depression.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Males and females between the ages of 18-80
- •DSM-IV diagnosis of Depressive Episode
- •Patients requiring TMS treatment as part of their psychiatric care
Exclusion Criteria
- •Comorbid DSM-IV primary diagnoses of schizoaffective disorder, schizophrenia or dementia.
- •Substance use disorder (abuse or dependence) with active use within the last 3 months
- •Severe or unstable medical illness.
- •MRI contraindications as determined by MGH department of radiology.
Arms & Interventions
Unipolar Depression
Patients diagnosed with unipolar depression.
Intervention: Transcranial Magnetic Stimulation (Device)
Outcomes
Primary Outcomes
Changes in Functional Connectivity of Key Nodes in Depression
Time Frame: Through Treatment Completion, Average of 6 Weeks
Measured by Magnetic Resonance Imaging
Secondary Outcomes
No secondary outcomes reported
Investigators
Joan A Camprodon, MD MPH PhD
Chief of Division of Neuropsychiatry, Director of TMS Clinic, Director of Lab for Neuropsychiatry and Neuromodulation
Massachusetts General Hospital